Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12098191 | 0.84 | TNFRSF1A (0.40) | ABCG2KMT2ATNFRSF1ANFE2L2CYP1A1 | |
| SCHEMBL3857395 | 0.81 | NFE2L2 (0.45) | ABCG2KMT2ATNFRSF1ANFE2L2 | |
| SCHEMBL3855734 | 0.80 | NFE2L2 (0.33) | ABCG2TNFRSF1ANFE2L2CYP1A1CYP1A2 | |
| SCHEMBL3856121 | 0.79 | NFE2L2 (0.43) | ABCG2KMT2ATNFRSF1ANFE2L2 | |
| SCHEMBL12098212 | 0.76 | TNFRSF1A (0.34) | ABCG2TNFRSF1ANFE2L2CYP1A1CYP1A2 | |
| SCHEMBL3861970 | 0.76 | NFE2L2 (0.32) | ABCG2TNFRSF1ANFE2L2 | |
| SCHEMBL1620557 | 0.76 | CA1 (0.39) | TNFRSF1A | |
| SCHEMBL3860018 | 0.75 | NFE2L2 (0.44) | ABCG2KMT2ATNFRSF1ANFE2L2CYP1A1 | |
| SCHEMBL12098004 | 0.74 | TNFRSF1A (0.33) | ABCG2TNFRSF1ANFE2L2 | |
| SCHEMBL3856248 | 0.71 | MDM2 (0.40) | ABCG2TNFRSF1ANFE2L2CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589123-B2 | Chemical compounds | PHYTOPHARM PLC (GB) | 2009-09-15 | — | — | US | disclosed |
| CN-101511350-A | Dioxo-alkanes and dioxo-alkenes | PHYTOPHARM PLC (GB) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046311-A2 | DIOXO-ALKANES AND DIOXO-ALKENES | Phytopharm Plc (GB) | 2009-04-15 | — | — | EP | disclosed |
| US-20080045591-A1 | Chemical Compounds | VECTURA LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| WO-2008003978-A2 | DIOXO-ALKANES AND DIOXO-ALKENES | PHYTOPHARM PLC (GB) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045591-A1 | Chemical Compounds | CYP11B1, CYP11B2, CYP2S1 | ABCG2 39/4885KMT2A 3581/4885TNFRSF1A 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.